Last reviewed · How we verify
Lenacapavir long-acting
Lenacapavir is a first-in-class HIV capsid inhibitor that binds to the HIV capsid protein and blocks the uncoating of viral RNA, preventing early steps of HIV replication.
Lenacapavir is a first-in-class HIV capsid inhibitor that binds to the HIV capsid protein and blocks the uncoating of viral RNA, preventing early steps of HIV replication. Used for HIV-1 infection in treatment-experienced adults with multidrug-resistant HIV-1.
At a glance
| Generic name | Lenacapavir long-acting |
|---|---|
| Also known as | Yeztugo, Lenacapavir injection, PrEP, Injectable PrEP |
| Sponsor | ViiV Healthcare |
| Drug class | HIV capsid inhibitor |
| Target | HIV capsid protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Lenacapavir targets the HIV capsid, a critical viral structure that protects the viral genome during early infection. By inhibiting capsid uncoating, the drug prevents the release of viral RNA into the host cell cytoplasm, thereby blocking reverse transcription and integration. This novel mechanism of action is distinct from existing antiretroviral classes and provides activity against drug-resistant HIV strains.
Approved indications
- HIV-1 infection in treatment-experienced adults with multidrug-resistant HIV-1
Common side effects
- Injection site reactions
- Diarrhea
- Nausea
- Headache
Key clinical trials
- CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)
- ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention (NA)
- Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (PHASE2, PHASE3)
- HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots
- Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) (PHASE2)
- Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP (PHASE4)
- CAbotégravir LENacapavir DUal Long Acting (PHASE2)
- Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lenacapavir long-acting CI brief — competitive landscape report
- Lenacapavir long-acting updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI